Talaris Therapeutics is a biotechnology business based in the US. Talaris Therapeutics shares (TALS) are listed on the NASDAQ and all prices are listed in US Dollars. Talaris Therapeutics employs 84 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Talaris Therapeutics stock
How to buy Talaris Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TALS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Talaris Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Talaris Therapeutics stock price (NASDAQ: TALS)
Use our graph to track the performance of TALS stocks over time.Talaris Therapeutics shares at a glance
Latest market close | $0.00 |
---|---|
52-week range | $0.00 - $3.08 |
50-day moving average | $2.83 |
200-day moving average | $2.44 |
Wall St. target price | $20.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.74 |
Is it a good time to buy Talaris Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Talaris Therapeutics price performance over time
Historical closes compared with the close of $0 from 2023-11-16
1 week (2024-07-16) | nan% |
---|---|
1 month (2024-06-23) | nan% |
3 months (2024-04-23) | nan% |
6 months (2024-01-23) | nan% |
1 year (2023-07-27) | -100.00% |
---|---|
2 years (2022-07-27) | -100.00% |
3 years (2021-07-27) | 13.33 |
5 years (2019-07-23) | N/A |
Talaris Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -22.81% |
Return on equity TTM | -41.64% |
Profit margin | 0% |
Book value | $34.88 |
Market Capitalization | $119.6 million |
TTM: trailing 12 months
Talaris Therapeutics share dividends
We're not expecting Talaris Therapeutics to pay a dividend over the next 12 months.
Have Talaris Therapeutics's shares ever split?
Talaris Therapeutics's shares were split on a 1:10 basis on 19 October 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Talaris Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Talaris Therapeutics shares which in turn could have impacted Talaris Therapeutics's share price.
Talaris Therapeutics share price volatility
Over the last 12 months, Talaris Therapeutics's shares have ranged in value from as little as $0.0027 up to $3.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Talaris Therapeutics's is 2.1789. This would suggest that Talaris Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Talaris Therapeutics's beta into context you can compare it against those of similar companies.
- Catalyst Pharmaceuticals (CPRX.US): 0.703
- Alnylam Pharmaceuticals (ALNY.US): 0.37
- Neurocrine Biosciences (NBIX.US): 0.367
Talaris Therapeutics overview
As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc. , in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients.
Frequently asked questions
What percentage of Talaris Therapeutics is owned by insiders or institutions?Currently 11.91% of Talaris Therapeutics shares are held by insiders and 77.665% by institutions. How many people work for Talaris Therapeutics?
Latest data suggests 84 work at Talaris Therapeutics. When does the fiscal year end for Talaris Therapeutics?
Talaris Therapeutics's fiscal year ends in December. Where is Talaris Therapeutics based?
Talaris Therapeutics's address is: 570 South Preston Street, Louisville, KY, United States, 40202 What is Talaris Therapeutics's ISIN number?
Talaris Therapeutics's international securities identification number is: US87410C1045
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
Ask a question